Post Date: January 2, 2023

The field of marketed and evidence pharmaceutical options in the US has become robust—But there is more work that needs to be done.

The US Food and Drug Administration (FDA) Commissioner Robert Califf, MD says there remains a need to increase the pipeline for the following areas of medicine:

• Addiction
• Mental health
• Cardiovascular disease
• Pulmonary disease
• Renal disease
• Maternal-fetal health

There also remains a great deal of refining and optimizing—per the FDA avenues of disease indication—to achieve with some of these fields’ latest novel agents. Not all potential has been met for each drug; and not all potential drugs are yet available.

Early 2023, however, may serve as introduction to many promising new drugs and new indications.

Follow Glo Services LLC on:
Facebook: @gloservices.us
YouTube: Glo Services LLC